Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.68 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.61 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.53 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.49 |
| ▸ | FERMT2 | Q96AC1 | 2/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.40 |
| ▸ | STK17B | O94768 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14621314 | 0.89 | HRH3 (0.53) | HRH3STK17AHRH4TLR8NUDT1 | |
| SCHEMBL11286031 | 0.83 | NUDT1 (0.66) | HRH3STK17AHRH4TLR8NUDT1 | |
| SCHEMBL14619916 | 0.83 | TLR8 (0.66) | HRH3STK17AHRH4TLR8NUDT1 | |
| SCHEMBL21003173 | 0.82 | HRH4 (0.47) | HRH3STK17AHRH4TLR8NUDT1 | |
| SCHEMBL596209 | 0.81 | TLR8 (0.59) | HRH3STK17AHRH4TLR8NUDT1 | |
| SCHEMBL4647318 | 0.80 | HRH4 (0.48) | HRH3STK17AHRH4TLR8NUDT1 | |
| SCHEMBL11278962 | 0.80 | DNM2 (0.58) | HRH3STK17AHRH4TLR8NUDT1 | |
| SCHEMBL12330669 | 0.79 | HRH3 (0.55) | HRH3HRH4TLR8NUDT1FERMT2 | |
| SCHEMBL32678687 | 0.79 | HSD17B10 (0.50) | HRH3STK17AHRH4TLR8NUDT1 | |
| SCHEMBL32678680 | 0.79 | HSD17B10 (0.50) | HRH3STK17AHRH4TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174984-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-20140296204-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| WO-2013062945-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296204-A1 | CHEMICAL COMPOUNDS | DNMT1, DNMT3A, DNMT3B | HRH3 4123/4885STK17A 2807/4885HRH4 4210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.